Brief: Intellia Therapeutics Q3 Net Income USD -101.324 Million
06/11/2025 21:00
Nov 06 (Reuters) - Intellia Therapeutics Q3 operating income USD -111.477 million. Q3 collaboration revenue USD 13.782 million Q3 operating expenses USD 125.259 million Q3 basic EPS USD -0.92
Recent news on INTELLIA THERAPEUTICS
See all newsU.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
U.S. STOCKS ON THE MOVE-Qualcomm, Eaton, Howmet Aerospace
U.S. STOCKS ON THE MOVE-Sigma Lithium, Shake Shack, Novartis
Intellia rises after FDA grants fast-track status to its treatment for rare disease
Brief: Intellia Therapeutics Announces FDA Acceptance Of Biologics License Application With Priority Review For Lonvoguran Ziclumeran (Lonvo-Z) For Hereditary Angioedema (Hae)